{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:43:20Z","timestamp":1793781800145,"version":"4.6.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45456-7","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T01:55:04Z","timestamp":1774230904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In-silico identification of genetic variants associated with chronic lymphocytic leukemia for diagnostic and therapeutic applications"],"prefix":"10.1038","volume":"16","author":[{"given":"Md. Shariful","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Manir Hossain","family":"Mollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Asif","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md.","family":"Al Noman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Foysal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Abdul","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nibas Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Fahim","family":"Faysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Nurul Haque","family":"Mollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"45456_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"45456_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao, Y. et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed. Eng. Online. 21, 4 (2022).","journal-title":"Biomed. Eng. Online"},{"key":"45456_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3324\/haematol.2013.086066","volume":"99","author":"SA Parikh","year":"2014","unstructured":"Parikh, S. A. et al. Chronic lymphocytic leukemia in young (\u2264\u200955 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica 99, 140\u2013147 (2014).","journal-title":"Haematologica"},{"key":"45456_CR4","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1038\/s41467-019-11582-2","volume":"10","author":"HE Speedy","year":"2019","unstructured":"Speedy, H. E. et al. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nat. Commun. 10, 3615 (2019).","journal-title":"Nat. Commun."},{"key":"45456_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1053\/j.seminhematol.2013.09.007","volume":"50","author":"SL Slager","year":"2013","unstructured":"Slager, S. L. et al. Genetic susceptibility to chronic lymphocytic leukemia. Semin. Hematol. 50, 296\u2013302 (2013).","journal-title":"Semin. Hematol."},{"key":"45456_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00424","volume":"11","author":"E Cano-Gamez","year":"2020","unstructured":"Cano-Gamez, E. & Trynka, G. From GWAS to function: Using functional genomics to identify the mechanisms underlying complex diseases. Front. Genet. 11, 424 (2020).","journal-title":"Front. Genet."},{"key":"45456_CR7","doi-asserted-by":"publisher","first-page":"10933","DOI":"10.1038\/ncomms10933","volume":"7","author":"SI Berndt","year":"2016","unstructured":"Berndt, S. I. et al. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat. Commun. 7, 10933 (2016).","journal-title":"Nat. Commun."},{"key":"45456_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/ng.219","volume":"40","author":"MC Di Bernardo","year":"2008","unstructured":"Di Bernardo, M. C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204\u20131210 (2008).","journal-title":"Nat. Genet."},{"key":"45456_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ng.510","volume":"42","author":"D Crowther-Swanepoel","year":"2010","unstructured":"Crowther-Swanepoel, D. et al. Common variants at 2q37. 3, 8q24. 21, 15q21. 3 and 16q24. 1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132\u2013136 (2010).","journal-title":"Nat. Genet."},{"key":"45456_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2012-03-413591","volume":"120","author":"SL Slager","year":"2012","unstructured":"Slager, S. L. et al. Common variation at 6p21. 31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood 120, 843\u2013846 (2012).","journal-title":"Blood"},{"key":"45456_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ng.2652","volume":"45","author":"SI Berndt","year":"2013","unstructured":"Berndt, S. I. et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat. Genet. 45, 868\u2013876 (2013).","journal-title":"Nat. Genet."},{"key":"45456_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ng.2843","volume":"46","author":"HE Speedy","year":"2014","unstructured":"Speedy, H. E. et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 46, 56\u201360 (2014).","journal-title":"Nat. Genet."},{"key":"45456_CR13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/leu.2014.311","volume":"29","author":"GP Sava","year":"2015","unstructured":"Sava, G. P. et al. Common variation at 12q24. 13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia 29, 748\u2013751 (2015).","journal-title":"Leukemia"},{"key":"45456_CR14","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.3324\/haematol.2012.072140","volume":"98","author":"MC Di Bernardo","year":"2013","unstructured":"Di Bernardo, M. C. et al. Common genetic variation contributes significantly to the risk of developing chronic lymphocytic leukemia. Haematologica 98, e23\u2013e24 (2013).","journal-title":"Haematologica"},{"key":"45456_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00676-8","volume":"12","author":"P Garc\u00eda-Mart\u00edn","year":"2022","unstructured":"Garc\u00eda-Mart\u00edn, P. et al. Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: A CRuCIAL study. Blood Cancer J. 12, 79 (2022).","journal-title":"Blood Cancer J."},{"key":"45456_CR16","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado, J. et al. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica 105, 2205\u20132217 (2020).","journal-title":"Haematologica"},{"key":"45456_CR17","doi-asserted-by":"publisher","first-page":"D896","DOI":"10.1093\/nar\/gkw1133","volume":"45","author":"J MacArthur","year":"2017","unstructured":"MacArthur, J. et al. The new NHGRI-EBI catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res. 45, D896\u2013D901 (2017).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR18","unstructured":"Catalog, N-E-G. GWAS Summary Statistics for GCST90042803. (2021)."},{"key":"45456_CR19","unstructured":"Catalog, N-E-G. GWAS Summary Statistics for GCST90435647. (2018)."},{"key":"45456_CR20","unstructured":"Catalog, N-E-G. GWAS Summary Statistics for GCST90475611. (2024)."},{"key":"45456_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/hmg\/ddac245","volume":"32","author":"H Fitipaldi","year":"2023","unstructured":"Fitipaldi, H. & Franks, P. W. Ethnic, gender and other sociodemographic biases in genome-wide association studies for the most burdensome non-communicable diseases: 2005\u20132022. Hum. Mol. Genet. 32, 520\u2013532 (2023).","journal-title":"Hum. Mol. Genet."},{"key":"45456_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-genom-091212-153520","volume":"14","author":"OA Panagiotou","year":"2013","unstructured":"Panagiotou, O. A. et al. The power of meta-analysis in genome-wide association studies. Annu. Rev. Genom. Hum. Genet. 14, 441\u2013465 (2013).","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"45456_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193256","volume":"13","author":"Z Zhu","year":"2018","unstructured":"Zhu, Z. et al. Statistical power and utility of meta-analysis methods for cross-phenotype genome-wide association studies. PLoS One 13, e0193256 (2018).","journal-title":"PLoS One"},{"key":"45456_CR24","unstructured":"DSigDB: Drug SIGnatures DataBase."},{"key":"45456_CR25","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. DrugBank 6.0: The DrugBank knowledgebase for 2024. Nucleic Acids Res. 52, D1265\u2013D1275 (2024).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2015.02.019","volume":"15","author":"DS Sanford","year":"2015","unstructured":"Sanford, D. S. et al. Three newly approved drugs for chronic lymphocytic leukemia: Incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin. Lymphoma Myeloma Leuk. 15, 385\u2013391 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"45456_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082076","author":"M Marchetti","year":"2022","unstructured":"Marchetti, M. et al. Old and new drugs for chronic lymphocytic leukemia: Lights and shadows of real-world evidence. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11082076 (2022).","journal-title":"J. Clin. Med."},{"key":"45456_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075252","volume":"8","author":"M Shen","year":"2013","unstructured":"Shen, M. et al. Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One 8, e75252 (2013).","journal-title":"PLoS One"},{"key":"45456_CR29","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek, M. & Al-Sawaf, O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am. J. Hematol. 96, 1679\u20131705 (2021).","journal-title":"Am. J. Hematol."},{"key":"45456_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/932010","volume":"2013","author":"AP Gonz\u00e1lez-Rodr\u00edguez","year":"2013","unstructured":"Gonz\u00e1lez-Rodr\u00edguez, A. P. et al. Lenalidomide and chronic lymphocytic leukemia. Biomed Res. Int. 2013, 932010 (2013).","journal-title":"Biomed Res. Int."},{"key":"45456_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11095-022-03214-0","volume":"39","author":"M Zoulikha","year":"2022","unstructured":"Zoulikha, M. & He, W. Targeted drug delivery for chronic lymphocytic leukemia. Pharm. Res. 39, 441\u2013461 (2022).","journal-title":"Pharm. Res."},{"key":"45456_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051583","author":"P Iyer","year":"2023","unstructured":"Iyer, P. & Wang, L. Emerging therapies in CLL in the era of precision medicine. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15051583 (2023).","journal-title":"Cancers (Basel)"},{"key":"45456_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/nprot.2014.071","volume":"9","author":"TW Winkler","year":"2014","unstructured":"Winkler, T. W. et al. Quality control and conduct of genome-wide association meta-analyses. Nat. Protoc. 9, 1192\u20131212 (2014).","journal-title":"Nat. Protoc."},{"key":"45456_CR34","unstructured":"He, Y., Koido, M., Shimmori, Y. & Kamatani, Y. GWASLab: a Python package for processing and visualizing GWAS summary statistics. ; (2023)."},{"key":"45456_CR35","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/bioinformatics\/btq340","volume":"26","author":"CJ Willer","year":"2010","unstructured":"Willer, C. J., Li, Y. & Abecasis, G. R. METAL: Fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190\u20132191 (2010).","journal-title":"Bioinformatics"},{"key":"45456_CR36","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12879-024-09274-4","volume":"24","author":"X Cheng","year":"2024","unstructured":"Cheng, X. et al. Diagnostic value of BHI-V4 for heterogeneous and vancomycin-intermediate Staphylococcus aureus isolates: a systematic review and meta-analysis. BMC Infect. Dis. 24, 494 (2024).","journal-title":"BMC Infect. Dis."},{"key":"45456_CR37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","volume":"335","author":"JPA Ioannidis","year":"2007","unstructured":"Ioannidis, J. P. A., Patsopoulos, N. A. & Evangelou, E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335, 914\u2013916 (2007).","journal-title":"BMJ"},{"key":"45456_CR38","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/ejhg.2015.269","volume":"24","author":"J Fadista","year":"2016","unstructured":"Fadista, J. et al. The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. Eur. J. Hum. Genet. 24, 1202\u20131205 (2016).","journal-title":"Eur. J. Hum. Genet."},{"key":"45456_CR39","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jclinepi.2015.01.001","volume":"68","author":"A-S Jannot","year":"2015","unstructured":"Jannot, A.-S., Ehret, G. & Perneger, T. P\u2009<\u20095 \u00d7 10(-8) has emerged as a standard of statistical significance for genome-wide association studies. J. Clin. Epidemiol. 68, 460\u2013465 (2015).","journal-title":"J. Clin. Epidemiol."},{"key":"45456_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01261-5","volume":"8","author":"K Watanabe","year":"2017","unstructured":"Watanabe, K. et al. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 8, 1826 (2017).","journal-title":"Nat. Commun."},{"key":"45456_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"issue":"Suppl 1","key":"45456_CR42","doi-asserted-by":"publisher","first-page":"i38","DOI":"10.1093\/bioinformatics\/bti1016","volume":"21","author":"A Ben-Hur","year":"2005","unstructured":"Ben-Hur, A. & Noble, W. S. Kernel methods for predicting protein-protein interactions. Bioinformatics 21(Suppl 1), i38-46 (2005).","journal-title":"Bioinformatics"},{"key":"45456_CR43","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR44","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","volume":"39","author":"D Szklarczyk","year":"2011","unstructured":"Szklarczyk, D. et al. The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-8 (2011).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR45","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"issue":"Suppl 4","key":"45456_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"C-H Chin","year":"2014","unstructured":"Chin, C.-H. et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8(Suppl 4), S11 (2014).","journal-title":"BMC Syst. Biol."},{"key":"45456_CR47","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pi\u00f1ero","year":"2017","unstructured":"Pi\u00f1ero, J. et al. DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 45, D833\u2013D839 (2017).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nprot.2015.052","volume":"10","author":"J Xia","year":"2015","unstructured":"Xia, J., Gill, E. E. & Hancock, R. E. W. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat. Protoc. 10, 823\u2013844 (2015).","journal-title":"Nat. Protoc."},{"key":"45456_CR49","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute, I. et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 52, D174\u2013D182 (2024).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR50","doi-asserted-by":"publisher","first-page":"D304","DOI":"10.1093\/nar\/gkad1071","volume":"52","author":"G Skoufos","year":"2024","unstructured":"Skoufos, G. et al. TarBase-v9.0 extends experimentally supported miRNA\u2013gene interactions to cell-types and virally encoded miRNAs. Nucleic Acids Res. 52, D304\u2013D310 (2024).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrg1272","volume":"5","author":"A-L Barab\u00e1si","year":"2004","unstructured":"Barab\u00e1si, A.-L. & Oltvai, Z. N. Network biology: understanding the cell\u2019s functional organization. Nat. Rev. Genet. 5, 101\u2013113 (2004).","journal-title":"Nat. Rev. Genet."},{"key":"45456_CR52","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1093\/bioinformatics\/bth456","volume":"20","author":"EI Boyle","year":"2004","unstructured":"Boyle, E. I. et al. GO::TermFinder\u2013open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 20, 3710\u20133715 (2004).","journal-title":"Bioinformatics"},{"key":"45456_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"45456_CR54","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/gb-2003-4-9-r60","volume":"4","author":"G Dennis Jr","year":"2003","unstructured":"Dennis, G. Jr et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4, R60 (2003).","journal-title":"Genome Biol."},{"key":"45456_CR55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1107\/S0907444902003451","volume":"58","author":"HM Berman","year":"2002","unstructured":"Berman, H. M. et al. The Protein Data Bank. Acta Crystallogr. D Biol. Crystallogr. 58, 899\u2013907 (2002).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"45456_CR56","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi, M. et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439\u2013D444 (2022).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR57","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1093\/bioinformatics\/bts310","volume":"28","author":"A Volkamer","year":"2012","unstructured":"Volkamer, A. et al. DoGSiteScorer: A web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics 28, 2074\u20132075 (2012).","journal-title":"Bioinformatics"},{"key":"45456_CR58","doi-asserted-by":"publisher","first-page":"D1227","DOI":"10.1093\/nar\/gkad1040","volume":"52","author":"M Cannon","year":"2024","unstructured":"Cannon, M. et al. DGIdb 5.0: Rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms. Nucleic Acids Res. 52, D1227\u2013D1235 (2024).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR59","doi-asserted-by":"publisher","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","volume":"47","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 47, D1102\u2013D1109 (2019).","journal-title":"Nucleic Acids Res."},{"key":"45456_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell, M. D. et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4, 17 (2012).","journal-title":"J. Cheminform"},{"key":"45456_CR61","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791 (2009).","journal-title":"J. Comput. Chem."},{"key":"45456_CR62","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"45456_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf215","author":"A Ajadee","year":"2025","unstructured":"Ajadee, A. et al. In-silico discovery of type-2 diabetes-causing host key genes that are associated with the complexity of monkeypox and repurposing common drugs. Brief. Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbaf215 (2025).","journal-title":"Brief. Bioinform."},{"key":"45456_CR64","first-page":"23","volume":"7","author":"S Shityakov","year":"2014","unstructured":"Shityakov, S. & F\u00f6rster, C. In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter. Adv. Appl. Bioinform Chem. 7, 23\u201336 (2014).","journal-title":"Adv. Appl. Bioinform Chem."},{"key":"45456_CR65","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 1, 337\u2013341 (2004).","journal-title":"Drug Discov. Today Technol."},{"key":"45456_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"45456_CR67","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1021\/ci034243x","volume":"44","author":"JS Delaney","year":"2004","unstructured":"Delaney, J. S. ESOL: Estimating aqueous solubility directly from molecular structure. J. Chem. Inf. Comput. Sci. 44, 1000\u20131005 (2004).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"45456_CR68","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DEV Pires","year":"2015","unstructured":"Pires, D. E. V., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066\u20134072 (2015).","journal-title":"J. Med. Chem."},{"key":"45456_CR69","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1021\/ci980029a","volume":"38","author":"MD Wessel","year":"1998","unstructured":"Wessel, M. D. et al. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38, 726\u2013735 (1998).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"45456_CR70","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1021\/jm000292e","volume":"43","author":"WJ Egan","year":"2000","unstructured":"Egan, W. J., Merz, K. M. J. & Baldwin, J. J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43, 3867\u20133877 (2000).","journal-title":"J. Med. Chem."},{"key":"45456_CR71","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/00004647-199707000-00001","volume":"17","author":"WM Pardridge","year":"1997","unstructured":"Pardridge, W. M. Drug delivery to the brain. J. Cereb. blood flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 17, 713\u2013731 (1997).","journal-title":"J. Cereb. blood flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"45456_CR72","first-page":"28","volume":"5","author":"S Sharma","year":"2021","unstructured":"Sharma, S., Sharma, A. & Gupta, U. Molecular docking studies on the anti-fungal activity of allium sativum (Garlic) against mucormycosis (black fungus) by BIOVIA discovery studio visualizer 21.1. 0.0. Ann. Antivirals Antiretrovir. 5, 28\u201332 (2021).","journal-title":"Ann. Antivirals Antiretrovir."},{"key":"45456_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler, M. et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal. Transduct. Target. Ther. 10, 91 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"45456_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221922","author":"WF Li","year":"2024","unstructured":"Li, W. F. et al. BCL2i-based therapies and emerging resistance in chronic lymphocytic leukemia. Cells https:\/\/doi.org\/10.3390\/cells13221922 (2024).","journal-title":"Cells"},{"key":"45456_CR75","first-page":"456","volume":"10","author":"LE Robertson","year":"1996","unstructured":"Robertson, L. E. et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10, 456\u2013459 (1996).","journal-title":"Leukemia"},{"key":"45456_CR76","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.clml.2022.07.013","volume":"22","author":"R Bennett","year":"2022","unstructured":"Bennett, R., Thompson, E. & Tam, C. SOHO state of the art updates and next questions | Mechanisms of resistance to BCL2 inhibitor therapy in chronic lymphocytic leukemia and potential future therapeutic directions. Clin. Lymphoma Myeloma Leuk. 22, 795\u2013804 (2022).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"45456_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1226289","volume":"13","author":"SI Tantawy","year":"2023","unstructured":"Tantawy, S. I. et al. Targeting MCL-1 protein to treat cancer: Opportunities and challenges. Front. Oncol. 13, 1226289 (2023).","journal-title":"Front. Oncol."},{"key":"45456_CR78","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.275.5303.1129","volume":"275","author":"J Yang","year":"1997","unstructured":"Yang, J. et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275, 1129\u20131132 (1997).","journal-title":"Science"},{"key":"45456_CR79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4161\/auto.22399","volume":"9","author":"S Luo","year":"2013","unstructured":"Luo, S. & Rubinsztein, D. C. BCL2L11\/BIM: A novel molecular link between autophagy and apoptosis. Autophagy 9, 104\u2013105 (2013).","journal-title":"Autophagy"},{"key":"45456_CR80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore, V. et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117, 112\u2013121 (2007).","journal-title":"J. Clin. Invest."},{"key":"45456_CR81","first-page":"828","volume":"6","author":"A Reyes","year":"2023","unstructured":"Reyes, A. & Siddiqi, T. Targeting BCL2 pathways in CLL: A story of resistance and ingenuity. Cancer drug Resist. (Alhambra Calif) 6, 828\u2013837 (2023).","journal-title":"Cancer drug Resist. (Alhambra Calif)"},{"key":"45456_CR82","first-page":"210","volume":"15","author":"C Daniel","year":"2017","unstructured":"Daniel, C. & Mato, A. R. BCL-2 as a therapeutic target in chronic lymphocytic leukemia. Clin. Adv. Hematol. Oncol. 15, 210\u2013218 (2017).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"45456_CR83","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.2147\/JIR.S519885","volume":"18","author":"H Zhang","year":"2025","unstructured":"Zhang, H., Li, X. & Lin, L. Biological functions and clinical implications of CFLAR: From cell death mechanisms to therapeutic targeting in immune regulation. J. Inflamm. Res. 18, 4911\u20134928 (2025).","journal-title":"J. Inflamm. Res."},{"key":"45456_CR84","doi-asserted-by":"publisher","first-page":"30321","DOI":"10.3390\/ijms161226232","volume":"16","author":"Y Tsuchiya","year":"2015","unstructured":"Tsuchiya, Y., Nakabayashi, O. & Nakano, H. FLIP the switch: Regulation of apoptosis and necroptosis by cFLIP. Int. J. Mol. Sci. 16, 30321\u201330341 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"45456_CR85","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","volume":"21","author":"M MacFarlane","year":"2002","unstructured":"MacFarlane, M. et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21, 6809\u20136818 (2002).","journal-title":"Oncogene"},{"key":"45456_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1561102","volume":"15","author":"L Hu","year":"2025","unstructured":"Hu, L. et al. FAS mediates apoptosis, inflammation, and treatment of pathogen infection. Front. Cell. Infect. Microbiol. 15, 1561102 (2025).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"45456_CR87","unstructured":"Apoptosis Pathways in chronic lymphocytic leukemia: role of the microenvironment and therapeutic strategies. ; (2017)."},{"key":"45456_CR88","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fimmu.2016.00382","volume":"7","author":"E Volpe","year":"2016","unstructured":"Volpe, E. et al. Fas-fas ligand: checkpoint of t cell functions in multiple sclerosis. Front. Immunol. 7, 382 (2016).","journal-title":"Front. Immunol."},{"key":"45456_CR89","doi-asserted-by":"publisher","first-page":"309","DOI":"10.18632\/oncotarget.1480","volume":"5","author":"C Billard","year":"2014","unstructured":"Billard, C. Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget 5, 309\u2013325 (2014).","journal-title":"Oncotarget"},{"key":"45456_CR90","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2007-11-124065","volume":"112","author":"R Proto-Siqueira","year":"2008","unstructured":"Proto-Siqueira, R. et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood 112, 394\u2013397 (2008).","journal-title":"Blood"},{"key":"45456_CR91","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/0888-7543(91)90030-I","volume":"11","author":"A Milatovich","year":"1991","unstructured":"Milatovich, A. et al. Gene for lymphoid enhancer-binding factor 1 (LEF1) mapped to human chromosome 4 (q23-q25) and mouse chromosome 3 near Egf. Genomics 11, 1040\u20131048 (1991).","journal-title":"Genomics"},{"key":"45456_CR92","doi-asserted-by":"publisher","first-page":"649","DOI":"10.18632\/oncotarget.1619","volume":"5","author":"F Albano","year":"2014","unstructured":"Albano, F. et al. Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia. Oncotarget 5, 649\u2013658 (2014).","journal-title":"Oncotarget"},{"key":"45456_CR93","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.4081\/hr.2010.e3","volume":"2","author":"F Erdfelder","year":"2010","unstructured":"Erdfelder, F. et al. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol. Rep. 2, e3 (2010).","journal-title":"Hematol. Rep."},{"key":"45456_CR94","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2010-02-269878","volume":"116","author":"AJ Gutierrez","year":"2010","unstructured":"Gutierrez, A. J. et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 116, 2975\u20132983 (2010).","journal-title":"Blood"},{"key":"45456_CR95","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-21-3867","volume":"28","author":"DM Stephens","year":"2022","unstructured":"Stephens, D. M. et al. Selinexor combined with Ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. Clin. Cancer. Res. 28, 3242\u20133247 (2022).","journal-title":"Clin. Cancer. Res."},{"key":"45456_CR96","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing, Z. A. et al. Selinexor is effective in acquired resistance to Ibrutinib and synergizes with Ibrutinib in chronic lymphocytic leukemia. Blood 125, 3128\u20133132 (2015).","journal-title":"Blood"},{"key":"45456_CR97","unstructured":"Ibrutinib for CLL: Mechanism of action and clinical considerations."},{"key":"45456_CR98","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2217\/fon.14.51","volume":"10","author":"MS Davids","year":"2014","unstructured":"Davids, M. S. & Brown, J. R. Ibrutinib: A first in class covalent inhibitor of Bruton\u2019s tyrosine kinase. Future. Oncol. 10, 957\u2013967 (2014).","journal-title":"Future. Oncol."},{"key":"45456_CR99","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/sji.12333","volume":"82","author":"A Bergl\u00f6f","year":"2015","unstructured":"Bergl\u00f6f, A. et al. Targets for Ibrutinib beyond B Cell malignancies. Scand. J. Immunol. 82, 208\u2013217 (2015).","journal-title":"Scand. J. Immunol."},{"key":"45456_CR100","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.2147\/OTT.S249586","volume":"13","author":"H Zhou","year":"2020","unstructured":"Zhou, H. et al. Ibrutinib in chronic lymphocytic leukemia: Clinical applications, drug resistance, and prospects. Onco. Targets. Ther. 13, 4877\u20134892 (2020).","journal-title":"Onco. Targets. Ther."},{"key":"45456_CR101","first-page":"e70249","volume":"8","author":"S Okabe","year":"2025","unstructured":"Okabe, S. et al. Therapeutic potential of venetoclax and selinexor in targeting hypoxia-induced vulnerabilities in multiple myeloma. Cancer Rep. (Hoboken N J). 8, e70249 (2025).","journal-title":"Cancer Rep. (Hoboken N J)"},{"key":"45456_CR102","doi-asserted-by":"publisher","first-page":"16950","DOI":"10.1038\/s41598-023-44039-0","volume":"13","author":"C Vitale","year":"2023","unstructured":"Vitale, C. et al. Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia. Sci. Rep. 13, 16950 (2023).","journal-title":"Sci. Rep."},{"key":"45456_CR103","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/leu.2014.9","volume":"28","author":"Y Zhong","year":"2014","unstructured":"Zhong, Y. et al. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia 28, 1158\u20131163 (2014).","journal-title":"Leukemia"},{"key":"45456_CR104","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12859-021-04175-8","volume":"22","author":"J Zhong","year":"2021","unstructured":"Zhong, J. et al. A novel essential protein identification method based on PPI networks and gene expression data. BMC Bioinform. 22, 248 (2021).","journal-title":"BMC Bioinform."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45456-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45456-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45456-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:02:52Z","timestamp":1778425372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45456-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45456"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45456-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14545"}}